FDA Approves Linzess to Treat Constipation in Children, Teens

WEDNESDAY, June 14, 2023 (HealthDay News) -- The U.S. Food and Drug Administration approved Linzess (linaclotide) as a once-daily treatment for pediatric patients ages 6 to 17 years with functional constipation.
The approval was based on data from 328 participants who were randomly assigned (1:1) to receive Linzess or placebo. A statistically significant benefit and clinically meaningful improvement was seen for 12-week spontaneous bowel movement frequency rate with Linzess compared with placebo, with Linzess-treated patients showing a greater than twofold least squares mean change from baseline in spontaneous bowel movements per week (2.6 versus 1.3). Diarrhea was the most common adverse event reported (4 percent of Linzess-treated patients versus 2 percent of placebo-treated patients).
"Pediatric functional constipation is an all-too-common issue that physicians see every day, yet despite the tremendous distress it causes to our patients and their families, we haven't had an FDA-approved prescription treatment to offer until now," Jeffrey S. Hyams, M.D., from the Connecticut Children’s Medical Center and the University of Connecticut in Hartford, said in a statement. "The approval of Linzess for the treatment of functional constipation in pediatric patients ages 6 to 17 years old is a meaningful advancement for these young patients."
Expanded approval of Linzess was granted to Ironwood Pharmaceuticals.
Related Posts
New Clues to Sudden Unexplained Deaths in Young Kids
TUESDAY, Dec. 28, 2021 (HealthDay News) -- Every year in the United States, a...
Many Doctors Unaware of Benefits of E-Cigarettes for Quitting Smoking
MONDAY, April 18, 2022 (HealthDay News) -- Many physicians incorrectly believe...
Pfizer COVID Pill to Be Made, Sold Cheaply in 95 Poor Countries
https://consumer.healthday.com/b-11-16-pfizer-covi... Credit: HealthDay
Los ‘fans tóxicos’: cuando la adoración de su hijo por un famoso llega demasiado lejos
JUEVES, 13 de abril de 2023 (HealthDay News) -- No es nada nuevo que los jóvenes...